Premium
Leserbriefe
Author(s) -
Christina M. Ambros-Rudolph,
H. Peter Soyer,
Helmut Kerl
Publication year - 2006
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2006.06033.x
Subject(s) - citation , computer science , library science
Immunotherapy has assumed increasing importance in the therapy of malignant melanoma. The main reason is the high immunogenicity of the tumor itself, so that an immune response against the tumor often exists even without immune stimulation. The goal of modern immunotherapeutic approaches is to augment these anti-tumoral immune reactions to fight the tumor. Despite multiple successes, the ultimate breakthrough in the therapy of malignant melanoma has not yet been achieved. This overview summarizes the reasons for this lack of success and highlights future strategies for more successful therapy of malignant melanoma.